Forskning ved Københavns Universitet - Københavns Universitet

Forside

Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. / Specht, L; Nordentoft, A M; Cold, Søren; Clausen, N T; Nissen, N I.

I: British Journal of Cancer, Bind 55, Nr. 5, 1987, s. 535-539.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Specht, L, Nordentoft, AM, Cold, S, Clausen, NT & Nissen, NI 1987, 'Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy', British Journal of Cancer, bind 55, nr. 5, s. 535-539.

APA

Specht, L., Nordentoft, A. M., Cold, S., Clausen, N. T., & Nissen, N. I. (1987). Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. British Journal of Cancer, 55(5), 535-539.

Vancouver

Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI. Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. British Journal of Cancer. 1987;55(5):535-539.

Author

Specht, L ; Nordentoft, A M ; Cold, Søren ; Clausen, N T ; Nissen, N I. / Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. I: British Journal of Cancer. 1987 ; Bind 55, Nr. 5. s. 535-539.

Bibtex

@article{07747cd04ec611df928f000ea68e967b,
title = "Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy",
abstract = "One hundred and forty-two patients with Hodgkin's disease PS I or II were treated with total or subtotal nodal irradiation as part of a prospective randomized trial in the Danish National Hodgkin Study during the period 1971-83. They were followed till death or--at the time of this analysis--from 15 to 146 months after initiation of therapy. The initial tumour burden of each patient was assessed, combining tumour size of each involved region and number of regions involved. Tumour burden thus assessed proved to be the single most important prognostic factor with regard to disease free survival. Other known prognostic factors such as number of involved regions, mediastinal size, pathological stage, systemic symptoms, and ESR were related to tumour burden and lost their prognostic significance in a multivariate analysis. The only other factors of independent significance were histologic subtype and, to a lesser extent, sex. Combining tumour burden and histologic subtype made it possible to single out a group of patients with a very poor disease free survival. These patients also had a poorer survival from Hodgkin's disease and thus clearly candidates for additional initial treatment.",
author = "L Specht and Nordentoft, {A M} and S{\o}ren Cold and Clausen, {N T} and Nissen, {N I}",
note = "UI - 87271468LA - engPT - Clinical TrialPT - Journal ArticlePT - Randomized Controlled TrialDA - 19870901IS - 0007-0920SB - IMCY - ENGLAND",
year = "1987",
language = "Dansk",
volume = "55",
pages = "535--539",
journal = "B J C",
issn = "0007-0920",
publisher = "nature publishing group",
number = "5",

}

RIS

TY - JOUR

T1 - Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy

AU - Specht, L

AU - Nordentoft, A M

AU - Cold, Søren

AU - Clausen, N T

AU - Nissen, N I

N1 - UI - 87271468LA - engPT - Clinical TrialPT - Journal ArticlePT - Randomized Controlled TrialDA - 19870901IS - 0007-0920SB - IMCY - ENGLAND

PY - 1987

Y1 - 1987

N2 - One hundred and forty-two patients with Hodgkin's disease PS I or II were treated with total or subtotal nodal irradiation as part of a prospective randomized trial in the Danish National Hodgkin Study during the period 1971-83. They were followed till death or--at the time of this analysis--from 15 to 146 months after initiation of therapy. The initial tumour burden of each patient was assessed, combining tumour size of each involved region and number of regions involved. Tumour burden thus assessed proved to be the single most important prognostic factor with regard to disease free survival. Other known prognostic factors such as number of involved regions, mediastinal size, pathological stage, systemic symptoms, and ESR were related to tumour burden and lost their prognostic significance in a multivariate analysis. The only other factors of independent significance were histologic subtype and, to a lesser extent, sex. Combining tumour burden and histologic subtype made it possible to single out a group of patients with a very poor disease free survival. These patients also had a poorer survival from Hodgkin's disease and thus clearly candidates for additional initial treatment.

AB - One hundred and forty-two patients with Hodgkin's disease PS I or II were treated with total or subtotal nodal irradiation as part of a prospective randomized trial in the Danish National Hodgkin Study during the period 1971-83. They were followed till death or--at the time of this analysis--from 15 to 146 months after initiation of therapy. The initial tumour burden of each patient was assessed, combining tumour size of each involved region and number of regions involved. Tumour burden thus assessed proved to be the single most important prognostic factor with regard to disease free survival. Other known prognostic factors such as number of involved regions, mediastinal size, pathological stage, systemic symptoms, and ESR were related to tumour burden and lost their prognostic significance in a multivariate analysis. The only other factors of independent significance were histologic subtype and, to a lesser extent, sex. Combining tumour burden and histologic subtype made it possible to single out a group of patients with a very poor disease free survival. These patients also had a poorer survival from Hodgkin's disease and thus clearly candidates for additional initial treatment.

M3 - Tidsskriftartikel

VL - 55

SP - 535

EP - 539

JO - B J C

JF - B J C

SN - 0007-0920

IS - 5

ER -

ID: 19402381